U.S. FDA issues VAI classification to Natco Pharma’s FDF unit in Vizag
VAI is one of the three classifications, the U.S. FDA issues implying objectionable conditions or practices were found, during the inspection, but the regulator is not prepared to take or recommend any administrative or regulatory action
Account subscription benefits alongside Premium Stories, Editorials, Opinions and more.
Unlock these with Subscription
The View From India Looking at World Affairs from the Indian perspective.
First Day First Show News and reviews from the world of cinema and streaming.
Today's Cache Your download of the top 5 technology stories of the day.
Science For All The weekly newsletter from science writers takes the jargon out of science and puts the fun in!
Data Point Decoding the headlines with facts, figures, and numbers
THEdge At the cutting edge of education and careers
Health Matters Ramya Kannan writes to you on getting to good health, and staying there
Gender Agenda Stories from beyond the binary.
The Hindu On Books Books of the week, reviews, excerpts, new titles and features.
Published - November 20, 2026 07:28 pm IST - HYDERABAD
Natco Pharma’s finished dosage formulations manufacturing unit in Visakhapatnam has received U.S.
Food and Drug Administration’s establishment inspection report with a voluntary action indicated (VAI) classification.
The U.S.
FDA had conducted an inspection of the facility in Parawada, Visakhapatnam, from August 17-21 and issued Form-483 with four observations.
“We hereby notify the company has received EIR from the U.S.
FDA on the classification of the above referred inspection as VAI,” Natco Pharma said in a filing on Friday.
VAI is one of the three classifications, the U.S.
FDA issues implying objectionable conditions or practices were found, during the inspection, but the regulator is not prepared to take or recommend any administrative or regulatory action.
Official action indicated (OAI) is another classification and severest, among the three, calling for regulatory and/or administrative actions.
No action indicated (NAI) is the third classification and convey no objectionable conditions or practices were found during inspection.
business (general) / pharmaceutical / medicine / litigation and regulation
Terms & conditions | Institutional Subscriber
Comments have to be in English, and in full sentences.
They cannot be abusive or personal.
Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform.
If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles.
If you do not have an account please register and login to post comments.
Users can access their older comments by logging into their accounts on Vuukle.
Full detailed coverage is shown on the council website above. Source attribution: The Hindu – Business.
Back to all council news